Peripheral arterial disease with intermittent claudication — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• Semaglutide in peripheral arterial disease

  GLP-1 receptor agonist (acylated, long-acting)1 contributing trialfull monograph

  Maximum walking distance ratio to baseline 1.21 versus 1.08 with placebo at 52 weeks — Single trial; functional endpoint in a population able to perceive weight change.

  Moderate

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.